• Durable construction: stainless steel inside, toughened glass window, double doors.
• Engineered compressor system extends lifespan and maintains precise temperatures.
• Innovative heating technology provides consistent 3D thermal distribution.
• Functional interior includes lighting and a power outlet for added utility.
• Control system powered by a high-speed CPU for reliable, real-time adjustments.
• Program automation up to 99 hours facilitates complex experimental protocols.
• Multi-parameter alarm system acts as a vigilant safety guard.
• System retains user settings and allows for precise temperature calibration.
• Continuous self-monitoring technology prevents unforeseen downtime.
• Upgradeable to include a backup safety controller and a UV disinfection cycle.

*Notes:

10-segment temperature control program to realize temperature curve program running.

The inflow and outflow air speed is also adjustable.

The classic method for producing monoclonal antibodies—the hybridoma technique—is a multi-step process centered on the CO2 incubator. It begins with immunizing a mouse, then fusing its spleen-derived B-cells with immortal myeloma cells.

The fragile fusion product is plated in a selective medium (HAT medium) in multi-well plates. The incubator’s role is now critical. For 10-14 days, the hybridoma cells must be nurtured at 37°C, 5% CO2, and high humidity. The selective medium is harsh, and the emerging hybridomas are vulnerable. Stable conditions are needed for these cells to proliferate. Researchers screen the supernatant from each well for desired antibody secretion, a process that often involves repeated medium changes and re-incubation. Once positive clones are identified, they are transferred, diluted for cloning, and expanded—all within the protective, stable environment of the incubator.

Any contamination, temperature spike, or pH swing during this period can wipe out a unique, antibody-producing clone that took weeks to generate. Thus, the reliability of the incubator is directly linked to the success rate of obtaining the precious monoclonal antibody lines used in research, diagnostics, and therapy.